Brief: Guard Therapeutics Presents Pre-Clinical Results For ROSgard

Disruptive Pharma AB (publ)

14/11/2019 07:22

Nov 14(Reuters) - Guard Therapeutics  GUARD.ST :
    * SAID ON WEDNESDAY DATA SHOW POSITIVE TREATMENT RESULTS
WITH THE
ACTIVE SUBSTANCE IN ROSGARD IN SEVERAL PRECLINICAL MODELS FOR
PREVENTION OF ACUTE KIDNEY DAMAGE
    * A PHASE 1A STUDY IS CURRENTLY UNDERWAY
    * THE PLAN IS TO BE ABLE TO CONDUCT THE FIRST STUDY IN
PATIENTS
UNDERGOING CARDIAC SURGERY IN 2020

    
 Source text for Eikon:  urn:newsml:reuters.com:*:nBQN1wGCyn
    
 Further company coverage:  GUARD.ST  
   


 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10))